Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Vitrium is a proprietary, resorbable orthobiomaterial composed entirely of bioactive glass (specifically 13-93 bioactive glass). Developed by Bio2 Technologies, it is designed for use in musculoskeletal reconstructive surgeries, such as spinal fusion, where it serves as a structural, load-bearing scaffold. The material features a unique porous structure that facilitates bone remodeling by allowing for the gradual conversion of the implant into the patient's own natural bone, a process referred to as Total Biologic Fusion (TBF). Unlike traditional implants made of PEEK or titanium, Vitrium is fully resorbable and osteoconductive, harnessing the body's regenerative processes to achieve fusion without leaving foreign materials behind. It has been evaluated in clinical trials as a cervical interbody fusion device for patients with symptomatic degenerative cervical disc disease.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Vitrium.